Navigation Links
Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
Date:8/6/2013

ng three doses of AVP-923 for the treatment of central neuropathic pain in multiple sclerosis. Top-line results from this study are expected in the fourth calendar quarter of 2013.
  • The company entered into an exclusive North American license agreement for the development and commercialization of a novel Breath Powered™ intranasal delivery system containing low-dose sumatriptan powder to treat acute migraine (AVP-825). If approved, this product would be the first and only fast-acting, dry-powder nasal delivery form of sumatriptan.
  • Other EventsAvanir announced that on August 6, 2013, the Company approved the grant of stock options to new employees to purchase a total of 60,800 shares of common stock in the aggregate. The stock options were granted as inducements material to the new employees entering into employment with Avanir, as permitted under NASDAQ Listing Rule 5635(c)(4).

    Avanir granted to 12 new employees an option to purchase shares of Avanir's common stock with an exercise price equal the closing price per share of Avanir's common stock as reported by NASDAQ on August 6, 2013, the date of grant. Each of the options will vest with respect to one-quarter of the underlying shares on the first anniversary of the grant date and then with respect to the remaining shares quarterly thereafter over the following three years, assuming in each case the employee remains continuously employed by Avanir.

    Note to Investors: As previously announced, Avanir will hold a conference call to discuss fiscal 2013 third quarter financial results today, August 6, 2013, beginning at 1:30 p.m. Pacific Time. You can listen to this call by dialing 1-800 638-4817 for domestic callers or +1-617 614-3943 for international callers, and entering passcode 15448717. Those interested in listening to the conference call live via the internet may do so by visiting http://ir.avanir.com.

    About AVP-825
    AVP-825 is an
    '/>"/>

    SOURCE Avanir Pharmaceuticals, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related medicine technology :

    1. Avanir Pharmaceuticals to Participate in Two Conferences in August
    2. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    3. Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA
    4. Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences
    5. Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business Results
    6. Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call
    7. Avanir Pharmaceuticals Receives Positive CHMP Opinion for Approval of NUEDEXTA in Europe
    8. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
    9. AVANIR Pharmaceuticals To paticipate in two conferences in March
    10. Avanir Pharmaceuticals Reports Fiscal 2013 First Quarter Financial And Business Results
    11. Avanir Pharmaceuticals Announces Positive Interim Data From Pharmacokinetic Study With Next Generation Compound AVP-786
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... to Millennium Research Group (MRG), the global authority ... United States and European transcatheter embolization ... through 2022, with embolization particles representing one of ... drug-eluting beads (DEBs) and radioembolization spheres in interventional ...
    (Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... Technologies for Advanced Drug Delivery Systems -- ... http://www.reportlinker.com/p01940411/Global-Markets-and-Technologies-for-Advanced-Drug-Delivery-Systems----Focus-on-End-Users.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_Delivery_Technology STUDY OBJECTIVES ...
    (Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
    Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4
    ... 2, 2011 Doctors should consider using catheterization as ... in diagnosing children with heart defects, according to a ... (Logo: http://photos.prnewswire.com/prnh/20100222/AHSALOGO ) A catheter is ... and used in procedures such as angiography, in which ...
    ... Lpath, Inc. (OTCBB: LPTN), the category leader ... President and CEO, will present at RetailInvestorConferences.com.DATE: ... EDTLINK: , www.retailinvestorconferences.com >Click the red "register/ ... interactive online event where investors are invited to ...
    Cached Medicine Technology:Catheterization Recommended for Treating Pediatric Heart Conditions 2Catheterization Recommended for Treating Pediatric Heart Conditions 3Lpath, Inc. CEO to Present Live, Online at RetailInvestorConferences.com on May 5th 2Lpath, Inc. CEO to Present Live, Online at RetailInvestorConferences.com on May 5th 3
    (Date:4/18/2014)... discovery by Northwestern Medicine scientists could lead to potential ... in people with scleroderma. , Fibrosis, or scarring, ... of the skin and lungs can lead to serious ... concept for new therapeutic options centers on findings made ... who identified the role that a specific protein plays ...
    (Date:4/17/2014)... that could be used to provide relief from ... made the discovery when researching how pain occurs ... , Dr Marzia Malcangio said: "We have been ... our findings could help chemotherapy patients who suffer ... effect of some chemotherapy drugs (such as vincristine) ...
    (Date:4/17/2014)... California, San Diego School of Medicine report that older ... recent major loss are more likely to be compassionate ... is published in this month,s issue of the ... behaviors are associated with better health and well-being as ... to improve the outcomes of individuals whose deficits in ...
    (Date:4/17/2014)... Northwestern University synthetic biology team has created a ... programmable therapeutics that could travel the body and ... , Engineering cell-based, biological devices that monitor and ... clinical synthetic biology. However, no existing technology enabled ... patient,s physiological state and respond in a customized ...
    (Date:4/17/2014)... NY (April 16, 2014) The cause of neuronal ... new study proposes that neurons may be mistaken for ... system, similar to the way autoimmune diseases like type ... body,s cells. The study was published April 16, 2014, ... new, and likely controversial, idea in Parkinson,s disease; but ...
    Breaking Medicine News(10 mins):Health News:New clues on tissue scarring in scleroderma 2Health News:New pain relief targets discovered 2Health News:The ilk of human kindness 2Health News:Building 'smart' cell-based therapies 2Health News:Is Parkinson's an autoimmune disease? 2
    ... (PORTLAND, Ore.) October 27, 2008 Elderly people who have ... abstention from tobacco, moderate to higher income and no ... their old age, according to a study in ... Medical Sciences . , The first study of its ...
    ... took them were less likely to get venous thromboembolism ... of drugs widely used to lower cholesterol may have ... breast, lung, colon and other solid-organ cancers. , Research ... Philadelphia found that cancer patients taking statins had a ...
    ... Reduce the Risk of a Subsequent Stroke, AUSTIN, ... launch of The TIA (Transient Ischemic Attack) Center for,Stroke ... of its kind in,Central Texas -- in an effort ... TIA., A TIA is a "warning stroke" or ...
    ... Incomparable Nutrient Value for Less Than 25 Cents A ... ... just released by,consulting firm Booz & Company confirmed that U.S. consumers have ... one,third of consumers have made measurable cutbacks in frequent purchases,such as dining ...
    ... Data presented at the joint annual meeting of ICAAC and ... effective as Prevnar for,the seven shared serotypes, and provide expanded ... complete U.S. filing for pediatric use in the first,quarter of ... or possibly earlier, WASHINGTON, Oct. 27 Data from ...
    ... ... Finds, RICHMOND, Va., Oct. 27 Eighty-four ... funding will be an important factor in determining how they cast,their vote in ... to 64 sponsored by Genworth Financial, Inc.,(NYSE: GNW )., According to ...
    Cached Medicine News:Health News:Study reveals factors of exceptional health in old age 2Health News:Statins Lower Risk of Clots in Cancer Patients 2Health News:St. David's HealthCare Launches The TIA Center for Stroke Prevention at St. David's Medical Center 2Health News:St. David's HealthCare Launches The TIA Center for Stroke Prevention at St. David's Medical Center 3Health News:No Need to Forego Nutrition in Tight Economic Times 2Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 2Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 3Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 4Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 5Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 6Health News:Phase 3 Data Indicate Investigational 13-valent Vaccine May Broaden Protection Against Pneumoccocal Disease in Children Younger than Two 7Health News:Survey Reveals Long Term Care Key Issue for Voters in Presidential Election 2Health News:Survey Reveals Long Term Care Key Issue for Voters in Presidential Election 3
    Sterile perfluorocarbon for intraocular Application....
    Sterile Silicone Oil for Intraocular Application....
    Silikon 1000 (purified polydimethylsiloxane) is a highly purified long chain polydimethylsiloxane trimethylsiloxy terminated silicone oil. For use as a postoperative retinal tamponade during vitreore...
    Round knurled handle. Overall length 130 mm....
    Medicine Products: